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l. 
A publication may disclose a class of chemical substances, in 
general terms. Subsequently, an inventor may single out selected 
compound(s) as having some special property not possessed by 
the class as a whole. This creates a problem with regard to the 
competing rights of the original publisher, the later inventor 
and the general public: specifically, what patent monopoly 
(if any) is the later inventor entitled to? This paper examines 
a recent New Zealand judgment, which was concerned with this 
problem (admittedly in a limited sense, as the original publisher 
and the later inventor were the same company, or employees 
thereof). 
I. 
A. 
l. 
INTRODUCTION 
8 c)rk(J r ouncl 
History of the case 
A patent application in New Zealand undergoes the following 
procedure on its passage to eventual grant: 
(a) Filing of the application, accompanied by a specification -
sections 8 and 9. 
(b) Examination - section 12. 
(c) Acceptance (after any objections arising from step (b) 
have been overcome) - section 20(1). 
(d) Publication - section 20(2). 
(e) Possible opposition, by any interested party - section 21. 
(f) Grant of the patent (after any opposition, in step (c), has 
been overcome) - section 27. 
2 . 
The case under review relates to one of Beecham's patent 
applications . Beecham filed Application No. 157516 in New Zealand 
on 18 August 1969 . The application related to Amoxycillin, 
a synthetic penicillin. Being a convention application, it 
claimed priority from the corresponding application filed in the 
United Kingdom on 23 August 1968. 1 The New Zealand application 
was accepted on 24 February 1972 . The monopoly sought is 
defined by the claims of the complete specification . The 
claims of the accepted specification were as follows : 
Claims 1-3: Amoxycillin and its salts and hydrates. 
Claims 4-5: A synergistic combination of one of these 
compounds with a penicillin. 
Beecham's application was opposed by Bristol, initially on 
three grounds . The ground of insufficiency had been dropped 
by the time the case reached the Court of Appeal; the opposition 
at this stage of the proceedings was on the grounds of prior 
publication and obviousness, only. For both grounds, the 
document relied on was Beecham's British Patent No . 978,178 
(hereafter referred to as the "Beecham OMP patent") . That 
patent was published on 5 May 1965 (i . e. before the priority 
date of the application in suit) . The Beecham OMP patent has 
a general formula which includes Amoxycillin (and various other 
compounds) within its scope. 
is not specifically disclosed . 
The preparation of Amoxycillin 
The outcome of the opposition proceedings was that Beecham ' s 
patent was sealed on 21 October 1982 . However, the patent monopoly 
granted was considerably more restricted than that which had 
been applied for . 
3. 
2. General 
The synthetic penicillin compound, Amoxycillin, has been a 
resounding commercial success. According to a Bristol 
affidavit, Amoxycillin trihydrate 2 topped the list of major 
drug prescriptions (other than hospital medicines) in New 
3 
Zealand for the year ended 31 March 1979. A valid patent 
gives the owner the right to stop others from using his 
invention,
4 
unless a licensing agreement has been entered 
into. Amoxycillin is a widely-used and effective medicinal 
compound, so the patent rights had a commercial value which 
was worthy of a full-scale legal battle. As stated in the 
Court of Appeal judgment in the case under review, delivered 
5 by Cooke J.: 
"Amoxycillin has proved such a successful drug that 
it has led to litigation pn olmost a global scale 
between the parties. Litigation has taken place in at 
least 14 countries. The results have varied and in 
most countries appeals are still pending." 
Some of the more sigificant overseas proceedings are summarised 
below, in Parts 3-5. 
3. British contract case : Beecham Group Ltd. v. Bristol 
Laboratories International S.A. 6 
This case related to a licence agreement between the same 
parties (i.e. Beecham and Bristol) in 1959. The question 
in issue was whether Beecham were obliged to add the Beecham 
OMP patent and U.K. Patent No. 1,241,844 (the British Amoxycillin 
patent) to a list of scheduled patents, as inventions existing in 
4 • 
1959. The relationship between the Beecham OMP patent 
and the British Amoxycillin patent was not analysed to any 
great extent. The conclusion was that the subject matter of 
the Beecham OMP patent had not been invented in 1959. Hence, 
any subsequent developments described in the British Amoxycillin 
patent could not have been invented then. 
4 • British opposition case 
Application 7 
Beecham Group Ltd. 's (Amoxycillin) 
As in New Zealand, an initial claim was made to the compound 
itself, unrestricted to method of use. During the examination 
stage, however, the claim was amended to relate to a pharmaceutical 
composition adapted for oral administration to human beings, 
containing Amoxycillin as an active ingredient. Bristol's 
opposition on the grounds of prior publication and obviousness 
was rejected by a majority of the Court of Appeal. 
5 . Australian Amoxycillin application Beecham Laboratories Pty. 
L d I A 1· . 8 t . s pp ication 
Beecham's Australian application, as accepted, contained similar 
claims to its New Zealand counterpart. Bristol opposed the 
application. As a result of Bristol's submissions, the Assista~t 
Commissioner required the claims to be restricted. The claims 
were accordingly amended along the same lines as in the Oritish 
opposition case. The patent which was granted contained claims 
to pharmaceutical compositions adapted for oral administration, but 
no claims to the active compound per se. 
5 . 
B . Nature of the Proceedings 
Accepted pate n t applications are advertised in the Patent 
Office Journal, i n the form of abridgements . 
brief descriptions of the subject matter . 
Abridgements give 
The actual complete 
specifications are made available
9 for members of the public 
to i n spect at the same time as the Journal is issued . 
The provisions for opposition to the grant of a patent are 
set out i n section 21 of the Patents Act 1953 . Within three 
months of the date of publication of the comp l ete sp~cification, 
any person interested may give notice, to the Commissioner, of 
opposition to the grant of the patent on any of the ten 
1 0 specified grou n ds . Such proceedings provide a means for 
anyone with " a rea l , definite, and substantial interest 11 11 
to oppose the grant of the patent . 
Opposition would appear to be an important adj unc t to the 
pre - acceptance examination carried out in the Patent Office
12 -
the ground relied on can be something which was either missed 
or not fully argued during examination, or some matter (e . g. 
obviousness) which could not be raised at that stage. 
However, although oppositions are by no means uncommon, some 
h . . d b " b h l f h d" 
13 
aut orities are u ious a out t e va ue o · sue procee ings . 
The benefit of any doubt must be given to the applicant . If 
the patent is granted, the unsuccessful opponent can still bring 
. t. 14 a revocation ac ion ; an unsuccessful applicant has no 
comparable " second chance." Thus , a contested opposition will 
usually result in an amendment to the specification, rather than 
an outright refusal to grant the patent . The amendment is more 
likely to strengthen , rather than weaken, the resulting patent . 
6. 
The statutory grounds relied on in the case under review 
are as set out in paragraphs (b) and (e) of subsection (1) 
of section 21: 
"(b) That the invention, so far as claimed in any 
claim of the complete specification, has been 
published in New Zealand before the priority 
date of the claim -
(i) In any specification filed in pursuance of an 
application for a patent made in New Zealand ... : 
(ii) In any other document .. . 
(e) That the invention, so far as claimed in any claim 
of the complete specification, is obvious and 
clearly does not involve any inventive step having 
regard to matter published as mentioned in paragraph 
(b) of this subsection, or having regard to what was 
used in New Zealand before the priority date of the 
applicant's claim" 
(emphasis added). 
Only novelty within New Zealand, and not worldwide novelty, 
is required. 
The Beecham OMP patent was a document within subparagraph (ii) 
of paragraph (b). 
C. Role of the Scientific Adviser 
Where matters of some technical difficulty are being considered, 
there is a provision for an independent scientific adviser to be 
appointed by the court or judge, at its or his discretion or 
f b 11 . h d' 15 a ter request y a parties tot c procee 1ngs. The job of 
the scientific adviser is to "inquire and report upon any questions 
7. 
of fact or opinion not involving questions of law or construction " 
The scientific adviser must remain strictly neutral; 
not his place to judge the case. 
it is 
This was the first New Zealand case in which such an adviser 
had been appointed. Professor R.J. Ferrier, Professor ot 
Organic Chemistry at Victoria University of Wellington, was 
appointed for the Supreme Court hearing, and his services were 
retained for the subsequent appeal. He provided technical 
advice when required, rather than furnishing a formal report. 16 
Bristol were opposed to the appointment of a scientific adviser. 
Their counsel submitted that "the adviser could readily transgress 
the limits of his proper role and express views to the Judge 
which the parties may wish to challenge but would have no 
opportunity of doing 1117 
Certainly, the use made of the scientific adviser during the 
Supreme Court proceedings would have done nothing to allay 
Bristol's fears. The scientific adviser was consulted between 
the time of the hearing and the issuance of the judgment. 
Neither party would be aware of the content of these discussions. 
Doubtless, the consultation related only to technical matters, 
and did not influence the decision. 
that justice should not only be done, 
D. 
l. 
Prior Proceedings 
19 Decision of the Commissioner 
However, it is submitted 
18 but be seen to be done. 
It was held that Claim l (the claim to the compound per se) had 
been anticipated by the Oeecham OMP patent. All the claims were 
deemed to be obvious, having regard to the disclosure in that 
8. 
document. The Assistant Commissioner (who was the hearing 
officer in this case) could not "envisage any amendment of 
the claims which would save the application 
2. S C t . d t 21 upreme our JU gmen 
Barker J. completely overturned the Assistant Commissioner's 
decision. He held that there had been no prior publication and 
that Bristol had "not discharged its onus under s 21(1) (e) of 
the Act [of showin~ that the invention was obvious and clearly 
[ d i d] n o t i n v o l v e a n y i n v e n t i v e s t e p " ~ 2 
was directed to seal Beecham's patent. 
The Commissioner 
II. RELEVANT SPECIFICATIONS CHEMICAL BACKGROUND 
The penicillin compound, Ampicillin (disclosed in U.K. Patent 
Specification No. 902,703 and its Ne w Zealand counterpart, 
No. 129316) had been both widely-used and effective . Any 
contender to take its place would need to be at least as 
effective. 
The Beecham OMP patent related to compounds derived from 
Ampicillin by the addition of a hydroxy group (-OH) to th e 
benzene ring (-Qr) present in the parent molecule. 
There are three possible positions at which the hydroxy group 
can be added, i.e. o (ortho), m (meta) and p (p ara ), as shown in 
the preceding diagrctm. (Position 2 is equivalent to position 6, 
and position 3 is equivalent to position 5.) There are thus 
three completely separate compounds (structural isomers), each 
having diff erent physical and chPmical propPrtics . 
9. 
A further complication arises because each of these three 
compounds contains (in a different part of the molecule) what 
is termed an "asymmetric centre ". Hence, each compound is 
capable of resolution into two mirror images, which are termed 
optical isomers or epimers and may be labelled as dextro (+) 
and laevo (-). Epimers have identical physical and chemical 
properties, except for different reactions with other asymmetric 
compounds etc. That exception is an important one. It is 
well-known, in the pharmaceutical industry, that one optical 
isomer may form a more effective medicament than the other. 
The Beecham OMP patent disclosed all three structural isomers, 
each as a mixture of its two epimers. No specific method was 
given for isolating the individual epimers. The Beecham OMP 
patent was published in New Zealand on 5 May 1965. A 
corresponding New Zealand patent had not been applied for. 
The specification in suit (No. 157516) relates to the (-) epimer 
of the p-hydroxy compound, i.e. Amoxycillin. Amoxycillin had 
not been specifically disclosed in the Beecham OMP patent, but 
was within the ambit of the general formula depicted therein. 
The Amoxycillin application was a convention application, 
thereby entitled to a priority date of 23 August 1968. This 
priority date was later than the date on which the Beecham OMP 
patent was published in New Zealand. It was not, therefore, 
possible to overcome the prior publication and obviousness 
objections merely by showing that the Amoxycillin application's 
priority date was earlier than the publication date of the cited 
document. 
10. 
III. ISSUES 
A. Prior Publication 
1. Meaning of the term 
A prior publication must anticipate the invention as claimed, 
i.e. it mu& disclose all the features of the claimed invention. 
2. Statutory provisions 
According to section 2l(l)(b)(ii), prior publication is the 
publication in New Zealand, before the priority date of the claim 
in question, of the invention, as claimed in any claim of the 
complete specification. The publication can be in "any 
document" (with some exceptions, which are not relevant in this 
case). 23 
3. 
( a ) 
Case law 
24 
Hill v. Evans 
This case contains a useful discussion of what constitutes 
prior publication. In order to anticipate an alleged invention, 
the antecedent statement must contain sufficient information to 
allow "a person of ordinary knowledge of the subject 1125 to put 
the discovery into practice. Additional experimentation should 
not be necessary. If further practical details need to be 
worked out before applying the discovery, this "affords sufficient 
room for another valid patent 1126 
Even if a document suggests to the person skilled in the art that 
the preparation of a particular compound would be advantageous, 
it may be possible to obtain a valid patent if the method of 
preparation was not immediately apparent from that document. 
( b) 
11. 
General Tire & Rubber Co. v. Firestone Tyre and Rubber 
27 Co. Ltd. 
If the anticipation is by prior publication, both documents 
(i.e. the specification in suit and the alleged prior publication) 
t b t d t th ' l t bl' ' d 28 mus e cons rue as a eir re evan pu ication ates. 
"To anticipate the patentee's claim the prior publication 
must contain clear and unmistakeable directions to do 
what the patentee claims to have invented A 
signpost, however clear, upon the road to the patentee's 
invention will not suffice. The prior inventor must be 
clearly shown to have planted his flag at the precise 
destination before the patentee." 
This extract emphasises the difference between prio! publication 
and obviousness. If the earlier publication gives a clear 
indication that it would be desirable to follow a certain line 
of research, the later specification may be obvious, but will not 
have been prior published. 
(c) British contract case : Beecham Group Ltd.v. Bristol 
Laboratories International S.A. 29 
The House of Lords was not otliged to determine the validity or 
otherwise of any of the patents involved. The issue was whether, 
under a licence agreement between the two parties, Beecham were 
bound to add the Beecham OMP patent of 1962 and the Amoxycillin 
patent of 1968 to a list of scheduled patents, as inventions 
existing at the date of the agreement (i.e. in 1959). It was 
considered that there was no invention in a particular penicillin 
compound until it had been produced and its therapeutic 
characteristics had been ascertained. 
12. 
( d ) E.I. Du Pont de Nemours & Co. (Witsiepe's) Application 30 
The difference between the language used in the revocation 
. . 31 d th . t. . . 32 provisions an e opposi ion provisions is alluded to. 
According to the revocation provisions, "what is alleged to have 
been anticipated must lack novelty 'having regard to what was 
known or used' . . .,33 before the priority date of the patent in question. 
The opposition provisions could not have a wider scope than those 
for revocation. · The applicant must be given the benefit of 
any doubt at the opposition stage, because (unlike the opponent) 
he would have no further opportunity to present his argument. 
(An unsuccessful opponent can still .apply for revocationJ 
"C::]onsequently, 'has been published' in [the opposition 
provisions] must be construed as restricted to publication in 
circumstances in which what is alleged to have been published 
can be said to have been 34 'known or used'." 
A compound which has been predicted, but not actually manufactured, 
is not a "known substance ". Merely listing compounds within a 
general formula, without having manufactured them, would not 
amount to anticipation of those compounds. 
4. Test for prior publication 
In the case of a chemical compound, it would appear that th e 
compound has not been anticipated until it has actually been 
produced, and at . least some of its properties have been sp e cified. 
The subject matter of the specification in question must have been 
entirely disclosed in the earlier document. "A signpost upon 
the road to the patentee's invention 1135 is insufficient. 
13. 
5. Decision 
The objection of prior publication failed. Counsel for 
Bristol had argued that Amoxycillin was disclosed in the 
Beecham OMP patent as one of ~he two epimers in the p-hydroxy 
mixture. This argument was rejected. Amoxycillin had not 
been separately made or isolated. It would have been difficult, 
if not impossible, to isolate it from the mixture. Amoxycillin 
is normally manufactured directly from the appropriate epimeric 
forms of the starting materials (6 - aminopenicillanic acid 
and d...- amino - p - hydroxyphenylacetic acid). 
The writer submits that the decision in regard to this matter 
is correct. The case law makes it clear that it is insufficient 
for an alleged anticipating document to merely refer to the 
compound in question. It must be apparent from the document that 
. 36 the compound has been produced. · Preferably, a method of 
preparation and/or some properties of the compound will have 
been specified. 
Amoxycillin had not previously been produced (except as part of 
a mixture comprising equal amounts of another compound, from 
which it could not readily be isolated). 
been prior _ published. 37 
B. Obviousness 
1. Meaning of the term 
Therefore, it had not 
An invention is obvious if it lacks an inventive step. As this 
is a difficult test to apply, many attempts have been made to 
paraphrase the requirement. However, British courts have warned 
"against treating the words of much-quoted decisions as if they 
14. 
38 were the words of a statute ". 0 b v i o u s ·n e s· s i s t o b e " j u d g e d 
by the standard of a man skilled in the art concerned : competent, 
'good at his job', but not imaginative or of an inventive turn 
of mind 1139 
Various factors, e.g. fulfilment of a long-felt want, commercial 
success etc., can be advance~ as arguments against the 
obviousness of the invention. How convincing such arguments will 
be depends upon the court's assessment of the whole situation. 
Commercial success, for instance, may arise more from 
advertising than from the intrinsic merits of the invention. 
There is a danger that any invention may seem obvious in 
hindsight. Often, it is fairly simple to work back from the 
specification and see how the inventor gleaned his idea from 
various sources. This may not, however, mean that the idea was 
obvious when first proposed by the inventor. 
2 • Statutory provisions 
The grounds for opposition and for revocation are not identical. 
Section 2l(l)(e) (opposition): "That the invention is obvious 
and clearly does not involve any inventive step having regard 
to matter published ... or having regard to what was used in New 
Zealand before the priority date of the applicant's claim" 
(emphasis added). 
Section 4l(l)(f) (revocation): "That the invention is obvious 
and does not involve any inventive step having regard to what 
was known or used before the priority date of the claim in New 
Zealand " 
15. 
The ground for opposition cannot be widei in scope than the 
d f . 40 groun or revocation. A sp~cification should not be struck 
down for obviousness at the opposition stage, unless it is 
reasonably certain that it would not withstand a full-scale 
revocation action. 
3. Selection patents 
If a class of chemical substances has been disclosed in general 
terms, a later inventor may single out a selected group as having 
some special property not possessed by the class as a whole. A 
selection is only possible if no member of the selected group has 
been specifically disclosed before. 
4. 
( a ) 
Case law 
41 Sharp & Dohme Inc. v. Bo6ts Pure Drug Cu. Ltd. 
L d H th MR t d M C . l 42 or anwor .• quo e r. ripps as counse : 
111 [W]as it for all practical purposes obvious to any 
skilled chemist in the state of chemical knowledge 
existing at the date of . the patent which consists of 
the chemical literature available ... and his general 
chemical knowledge, that he could manufacture valuable 
therapeutic agents by making the [compounds in questiorJ? 111 
This has henceforth been known as the "Cripps question 11 
Applying this test to the application in suit, it would appear 
obvious, following publication of the Beecham OMP patent, that 
the manufacture of Amoxycillin could result in a "valuable 
the rape u tic agent ". However , this may not be s u ff i c i en t. It 
was strongly argued that it was not obvious to concentrate 
resources on this line of research, rather than on other equally 
"obvious" possibilities. 
16. 
(b) I.G. Farbenindustrie A.G.' s Patents 43 
Maugham J. cautioned that a selection patent was not inherently 
different from any other type of patent. It was still "open 
to attack on the usual grounds of want of subject-matter, want 
of utility, want of novelty and so forth 
However, he laid down three requirements for selection patents, 
which have been generally approved in subsequent ·decisions, and 
have acquired an authoritative nature: 45 
"First, a selection patent to be valid must be based on 
some substantial advantage to be secured by the use of 
( C ) 
the selected members ..•. Secondly, the whole of the 
selected members must possess the advantage in question. 
Thirdly, the selection must be in respect of a quality of 
a special character which can fairly be said to be peculiar 
to the selected group." 
46 Johns-Manville Corporation's Patent 
Diplock L.J. warned against paraphrasing the words of the Act. 
No single verbal formula was likely to be appropriate in all 
cases. However, he felt that "it is enough that the person versed 
in the art would assess the likelihood of success as sufficient 
to warrant actual trial If so, the invention is obvious. 
Obviousness will, therefore, depend very much on the facts of 
the case. This test does not help in the case under review -
the "likelihood of success" was a contentious point. 
17. 
( d ) Imperial Chemical Industries Ltd.(Howe's) Application 48 
This was a very similar case to the present one. The issue 
was whether a claim to an optically active isomer was obvious 
in the light of prior disclosure of racemic mixtures. It was 
held that, as there was nothing in the cited documents or 
elsewhere to suggest that resolution of the racemic mixture 
into its individual isomers might result in any benefit, the 
objection as to obviousness failed. 
The first two grounds for distinguishing this case given by 
the Assistant Commissioner in his decision on the Amoxycillin 
case are of minor importance. However, as he rightly pointed 
out in his third ground, the benefits of isolating the individual 
compounds from a mixture of epimers are well-known in penicillin 
chemistry. Often, one epimer is found to be more effective 
than the other. 
(e) British contract case : Beecham Group Ltd. v. Bristol 
Laboratories International S.A. 49 
The chain of appeal proceedings reached the House of Lords. In 
that judgment, Lord Wilberforce commented on chemical selection 
patents. He expressed the view that a general claim for 
therapeutic and antibiotic properties would not invalidate a 
f . . II 50 "subsequent more specific claim or specific properties 
The latter claim would constitute a different invention to that 
of the originating patent. 
18. 
(f) British opposition case Beecham Group Ltd}s (Amoxycillin) 
A 1 . t· 51 pp ica ion 
Orowne L.J. considered that the particular factual situation 
was . t 52 impor ant. 
"Beecham's behaviour U-n following several lines of 
research, and not merely concentrating on the preparation 
of Amoxycilli~ seems to me completely inconsistent with 
that of anyone who thought it was obvious that further 
research into the U3eecham OMP paten!J penicillins and in 
particular the para-minus epimer, might well produce the 
winner in the race to find a new and better successor to 
Ampicillin." 
He felt that neither the applica~ts nor the opponents had shown 
any particular interest in the subject matter of the Beecham OMP 
patent, when it was published. Browne L.J. concluded that the 
opinions as to obviousness given by Bristol's experts had "a 
strong element of hindsight, the dangers of which in this context 
are well known 1153 
Templeman L.J. presented a dissenting judgment. Beecham had 
argued that the inventive step lay in the preparation of 
Amoxycillin and the discovery of its high blood level absorption 
characteristics. According to Templeman L.J., this was not an 
inventive step in the light of the disclosure of the Beecham 
OMP patent. The subject matter of the Amoxycillin application 
was merely the result of routine testing. 11 \)] t was obvious 
that the best epimer irom the Beecham OMP patenU should be 
identified and tested in the form of a composition suitable for 
oral administration to human beings.
1154 
19. 
The majority and minority judgments disagree on whether the 
preparation of Amoxycillin was the result of following a 
non-obvious line of research, or was merely the result of 
routine testing. Templeman L.J. addressed his judgment to the 
further problem of the scope of the claims. Were the applicants 
entitled to claim compositions containing Amoxycillin, which 
were limited only to being suitable for oral administration 
(i.e. the form in which~ compound from the Beecham OMP 
patent might be expected to be administered)? 
5. Test for obviousness 
Tests derived from earlier cases may offer guidance, but should 
not be relied on. In the end, it is perhaps better to just 
look to the dictionary meaning of "obvious", i.e. "very plain 
Obviousness is a question of fact. 
should be considered. 
All relevant circumstances 
6. Decision 
In an opposition, the onus is on the opponent to show that the 
invention is obvious and clearly does not involve any inventive 
step. Bristol had not discharged that onus. 
Pharmaceutical research is long and expensive . Testing of a 
compound involves six separate stages, culminating in full 
toxicological study and clinical trials. 56 The Beecham OMP 
II 5 5 
patent was applied for in Britain in 1962, but it was not until 
1968 that Amoxycillin was tested in man and found to produce 
substantially higher blood levels than Ampicillin. 
20. 
Although Amoxycillin was the culmination of an obvious line 
of rese arch , the invention itself was deemed not to be obvious, 
and to involve an inventive step, as a sufficiently distinctive 
advantage had been discovered. 
Scope of the Patent C. 
l. Case law : The Mullard Radio Valve Co., Ltd, v. Philco Radio 
d T l . . C t· f G t B · · L d 57 an e evision orpora ion o rea ritain, t . 
An inventor is "not entitled to claim a monopoly more extensive 
than is necessary to protect that which he has himself said is 
h . . t. ,, 58 is inven ion . The invention lay in the discovery that a 
particular juxtaposition of components gave new and useful 
results. Th erefore, the article was to be claimed with reference 
to that juxtaposition, only. 
2. Decision 
In the case under review, the invention lay in the unique 
advantage of Amoxycillin, i.e. its high oral absorbability in 
man. It was this advantage which overcame the objection of 
obviousness and lack of inventive step . Accordingly, the scope 
of the patent should be limited to the use of the compound in 
a composition for oral administration to human beings. 
Bristol's appeal was allowed, but only to a limited extent . 
The patent should not be sealed in the form initially applied 
for. The claims should be appropriately restricted. 
3. Subsequent ev ents 
By order of the Court of Appeal, the claims of the Amoxycillin 
specification have now been amended. The present claims take the 
21. 
same form as those allowed in the United Kingdom, Australia, 
and also South Africa. The principal claim, as amended, reads: 
IV. 
"A pharmaceutical composition adapted for oral 
administration to human beings containing as an 
active ingredient Gmoxycilli~ or a non-toxic ... 
salt thereof, the said \!-moxycillin or salt thereo-iJ 
being substantially free of the corresponding (+) 
epimeric form." 
RATIO 
There may be a valid selection patent derived from a relatively 
small originating class of compounds, provided that: 
1. The particular compound(s) selected have not been 
actually produced previously. 
2. The selected compound(s) share an unexpected and useful 
property, which is stated in the specification and is 
not possessed by othEr members of the originating class. 
3. Sufficient time and labour has been involved in producing 
the compound(s) and determining the property selected for. 
4. The scope of the claimed invention is appropriately 
limited. The compound(s) per se cannot be claimed. The 
claims must have some link with the property selected for. 
The first two factors are the normal standards for any selection 
patent. The remaining factors are additional standards, necessary 
because the selection is made from a relatively small originating 
class. 
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V. CONCLUSIONS 
A. Was the Decision Reasonab~ and Fair? 
In attempting to answer this question, two hypothetical 
situations and the actual situation pertaining in New Zealand 
will be considered. 
1. What if the earliff publication had been a current New Zealand 
patent, not belonging to Beecham? How would the earlier 
patentee feel? It is probably reasonable to reward the time 
and effort taken to produce the particular preferred isomer, 
especially as its favourable properties were not apparent 
until after it had been produced. However, the claims which 
were eventually allowed were only limited to compositions 
"adapted for oral administration" - this is probably the most 
common form of administration of penicillin compounds. If 
the actual compound could not be claimed on the grounds of 
obviousness, might not the patentee be somewhat disgruntled 
at the allowance of claims to the compound's principal (and 
obvious, for a penicillin compound) use? This situation would 
be ameliorated to some extent, as the Amoxycillin patent 
would be prior- claimed by the earlier patent. 59 As each 
patentee, in marketing Amoxycillin, would be infringing the 
other's patent, they would need to come to a cross-licensing 
arrangement. 
2. What if the Beecham OMP patent had actually been a New 
Zealand patent, still in Beecham's name (cf. the situation in 
the United Kingdom)? Is it fair to allow an extension of 
3 . 
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the monopoly period by means of such a selection patent? 
Should the later patent be limited to a patent of addition, 60 
which would expire at the end of the main patent's term? 
However, such a limitation would seem to be unwarranted in 
view of the Court of Appeal's decision with regard to 
b . 61 o viousness. 
The actual New Zealand situation . Beecham neglected to 
file a New Zealand equivalent to the Beecham OMP patent . Is 
it fair that they should be granted a monopoly by this 
indirect method (through the Amoxycillin patent)? 
As with any selection patent, there is an element of "unfairness" 
in this decision . The unfairness is more evident in this case, 
because the use of the selected compound has not been limited to 
one which would be inappropriate for oth~ members of the 
originating class . 
B . Significance : Interpretation of Chemical Specifications 
It is common for chemical specifications to include general 
formulae, covering many possible compounds . A patentee may not 
have a complete monopoly, except with respect to compounds which 
have been actually produced, and for which some properties have 
been specified . However, the decision in this case has probably 
not d r astically changed the prevailing situation . This problem 
has existed since the introduction of the concept of a 
" selection patent 1162 
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C. Was the Decision Correct? 
There may be some justification for allowing a selection from a 
fairly limited originating class, especially in the pharmaceutical 
field, where testing standards are rigorous. However, with regard 
to obviousness, the dissenting judgment of Templeman L.J. in 
the British opposition case 63 is convincing. 
In the present case, it was held that the claims should have some 
link with the property selected for. The amended claims do not 
appear to satisfy this requirement. Any compound within the 
scope of the originating Beecham OMP patent might be expe ct ed 
to be administered in the form of "[a] pharmaceutical composition 
adapted for oral administration •.. " . The invention as claimed 
does not relate to an unexpected property of Amoxycillin. 
It is difficult to see how this objection could be overcome . 
The actual unexpected property is high oral absorbability in 
man. This is an intrinsic property of the compound, rather than 
a pointer to any particular formulation more limited in scope than 
that of the presently-allowed claims. Claims to "[a] pharmaceutical 
composition adapted for oral administration to human beings and 
having high oral absorbability in human beings ... " would, in 
practical terms, be identical to the present composition claims . 
In conclusion, it would appear that a valid selection can be made 
in a case similar to that of Amoxycillin, but only if the property 
involved is substantially different from the properties of the 
other compounds of the originating class. The property which 
validates the selection must be apparent from the invention 
as claimed . 
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